TG
Therapeutic Areas
Mochida Pharmaceutical Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Fostamatinib (TAK-659 / M2951) | Immune Thrombocytopenia (ITP) | Approved |
| Fostamatinib | Warm Autoimmune Hemolytic Anemia (wAIHA) | Phase 3 |
| MO-8282 | Atopic Dermatitis | Phase 2 |
| MOB-015 (Tirbanibulin) | Actinic Keratosis | Approved |
| MOR-107 | Solid Tumors | Phase 1/2 |
| MOR-202 (Daratumumab biosimilar) | Multiple Myeloma | Clinical Development |
Leadership Team at Mochida Pharmaceutical
YM
Yuji Mochida
Representative Director, President and CEO
KT
Kazunari Tsunaba
Representative Director, Senior Managing Executive Officer
YK
Yoshihiko Katsuyama
Director, Senior Managing Executive Officer
HN
Hiroshi Noguchi
Director, Senior Managing Executive Officer
YO
Yoshihiro Oyamada
Director, Managing Executive Officer
KM
Kazuhiko Mori
Director, Managing Executive Officer
YS
Yoshihiko Sato
Director, Managing Executive Officer
KK
Kiyoshi Kikuchi
Standing Corporate Auditor
YM
Yoshihiro Miyata
Corporate Auditor
YO
Yoshio Otsuka
Corporate Auditor